ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels

British Journal of Cancer

Volumn 112, Issue 6, 2015, Pages 1059-1066

  Rondeau, S ^a   Vacher, S ^a   De Koning, L ^a   Briaux, A ^a   Schnitzler, A ^a   Chemlali, W ^a   Callens, C ^a   Lidereau, R ^a   Bieche I ^a,b  

^a INSTITUT CURIE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

ATM; breast cancer; DNA DSB repair; prognosis

Indexed keywords

ATM PROTEIN; HISTONE H2AX; MESSENGER RNA; MICRORNA; MICRORNA 100; MICRORNA 101; MICRORNA 106A; MICRORNA 181A2; MICRORNA 181B1; MICRORNA 18A; MICRORNA 203; MICRORNA 223; MICRORNA 26A; MICRORNA 26B; MICRORNA 27A; MICRORNA 421; MRE11 PROTEIN; NBN PROTEIN; PROTEIN; RAD50 PROTEIN; TP53BP1 PROTEIN; UNCLASSIFIED DRUG; XRCC5 PROTEIN; ATM PROTEIN, HUMAN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; MIRN203 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CONTROLLED STUDY; CORRELATIONAL STUDY; DOUBLE STRANDED DNA BREAK; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BREAST NEOPLASMS; CARCINOMA; DNA REPAIR; DOWN REGULATION; GENETICS; MIDDLE AGED; PROGNOSIS; SIGNAL TRANSDUCTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA; CELL CYCLE PROTEINS; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; HUMANS; MICRORNAS; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84925292902     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.60     Document Type: Article

References (43)

1. Akbani R, Becker KF, Carragher N, Goldstein T, de Koning L, Korf U, Liotta L, Mills GB, Nishizuka SS, Pawlak M, Petricoin 3rd EF, Pollard HB, Serrels B, Zhu J (2014) Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (reverse phase protein array) society. Mol Cell Proteomics 13: 1625-1643.
2. Beggs AD, Domingo E, McGregor M, Presz M, Johnstone E, Midgley R, Kerr D, Oukrif D, Novelli M, Abulafi M, Hodgson SV, Fadhil W, Ilyas M, Tomlinson IP (2012) Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN. Oncotarget 3: 1348-1355.
3. Bieche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R, Vidaud M (1999) Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 45: 1148-1156.
4. Bieche I, Parfait B, Laurendeau I, Girault I, Vidaud M, Lidereau R (2001a) Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene 20: 8109-8115.
5. Bieche I, Parfait B, Le Doussal V, Olivi M, Rio MC, Lidereau R, Vidaud M (2001b) Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. Cancer Res 61: 1652-1658.
6. Bieche I, Tozlu S, Onody P, Driouch K, Vidaud M, Lidereau R (2004) Expression of PEA3/E1AF/ETV4, an Ets-related transcription factor, in breast tumors: evidence of MMP2, NRG1 and CGB as major transactivated target genes. Carcinogenesis 25: 405-411.
7. Bisso A, Faleschini M, Zampa F, Capaci V, De Santa J, Santarpia L, Piazza S, Cappelletti V, Daidone M, Agami R, Del Sal G (2013) Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle 12: 1679-1687.
8. Bueno RC, Canevari RA, Villacis RA, Domingues MA, Caldeira JR, Rocha RM, Drigo SA, Rogatto SR (2014) ATM down-regulation is associated with poor prognosis in sporadic breast carcinomas. Ann Oncol 25: 69-75.
9. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401-404.
10. Di Francesco A, De Pitta C, Moret F, Barbieri V, Celotti L, Mognato M (2013) The DNA-damage response to gamma-radiation is affected by miR-27a in A549 cells. Int J Mol Sci 14: 17881-17896.
11. Finak G, Sadekova S, Pepin F, Hallett M, Meterissian S, Halwani F, Khetani K, Souleimanova M, Zabolotny B, Omeroglu A, Park M (2006) Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res 8: R58.
12. Flanagan JM, Munoz-Alegre M, Henderson S, Tang T, Sun P, Johnson N, Fletcher O, Dos Santos Silva I, Peto J, Boshoff C, Narod S, Petronis A (2009) Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. Hum Mol Genet 18: 1332-1342.
13. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: pl1.
14. Gilardini Montani MS, Prodosmo A, Stagni V, Merli D, Monteonofrio L, Gatti V, Gentileschi MP, Barila D, Soddu S (2013) ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. J Exp Clin Cancer Res 32: 95.
15. Grabsch H, Dattani M, Barker L, Maughan N, Maude K, Hansen O, Gabbert HE, Quirke P, Mueller W (2006) Expression of DNA doublestrand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer. Clin Cancer Res 12: 1494-1500.
16. Guo P, Lan J, Ge J, Nie Q, Guo L, Qiu Y, Mao Q (2014) MiR-26a enhances the radiosensitivity of glioblastoma multiforme cells through targeting of ataxia-telangiectasia mutated. Exp Cell Res 320: 200-208.
17. Guo X, Yang C, Qian X, Lei T, Li Y, Shen H, Fu L, Xu B (2013) Estrogen receptor alpha regulates ATM Expression through miRNAs in breast cancer. Clin Cancer Res 19: 4994-5002.
18. Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36.
19. Hu H, Du L, Nagabayashi G, Seeger RC, Gatti RA (2010) ATM is downregulated by N-Myc-regulated microRNA-421. Proc Natl Acad Sci USA 107: 1506-1511.
20. Kim H, Saka B, Knight S, Borges M, Childs E, Klein A, Wolfgang C, Herman J, Adsay VN, Hruban RH, Goggins M (2014) Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis. Clin Cancer Res 20: 1865-1872.
21. Kubota E, Williamson CT, Ye R, Elegbede A, Peterson L, Lees-Miller SP, Bebb DG (2014) Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines. Cell Cycle 13: 2129-2137.
22. Lee KW, Tsai YS, Chiang FY, Huang JL, Ho KY, Yang YH, Kuo WR, Chen MK, Lin CS (2011) Lower ataxia telangiectasia mutated (ATM) mRNA expression is correlated with poor outcome of laryngeal and pharyngeal cancer patients. Ann Oncol 22: 1088-1093.
23. Liang L, Zhu J, Zaorsky NG, Deng Y, Wu X, Liu Y, Liu F, Cai G, Gu W, Shen L, Zhang Z (2014) MicroRNA-223 enhances radiation sensitivity of U87MG cells in vitro and in vivo by targeting ataxia telangiectasia mutated. Int J Radiat Oncol Biol Phys 88: 955-960.
24. Lin F, Li R, Pan ZX, Zhou B, Yu de B, Wang XG, Ma XS, Han J, Shen M, Liu HL (2012) miR-26b promotes granulosa cell apoptosis by targeting ATM during follicular atresia in porcine ovary. PLoS One 7: e38640.
25. Mansour WY, Bogdanova NV, Kasten-Pisula U, Rieckmann T, Kocher S, Borgmann K, Baumann M, Krause M, Petersen C, Hu H, Gatti RA, Dikomey E, Dork T, Dahm-Daphi J (2013) Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinoma. Radiother Oncol 106: 147-154.
26. Ng WL, Yan D, Zhang X, Mo YY, Wang Y (2010) Over-expression of miR-100 is responsible for the low-expression of ATM in the human glioma cell line: M059J. DNA Repair (Amst) 9: 1170-1175.
27. Pal R, Srivastava N, Chopra R, Gochhait S, Gupta P, Prakash N, Agarwal G, Bamezai RN (2010) Investigation of DNA damage response and apoptotic gene methylation pattern in sporadic breast tumors using high throughput quantitative DNA methylation analysis technology. Mol Cancer 9: 303.
28. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38: 873-875.
29. Salimi M, Mozdarani H, Majidzadeh K (2012) Expression pattern of ATM and cyclin D1 in ductal carcinoma, normal adjacent and normal breast tissues of Iranian breast cancer patients. Med Oncol 29: 1502-1509.
30. Shiloh Y, Ziv Y (2013) The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 14: 197-210.
31. Song L, Lin C, Wu Z, Gong H, Zeng Y, Wu J, Li M, Li J (2011) miR-18a impairs DNA damage response through downregulation of ataxia telangiectasia mutated (ATM) kinase. PLoS One 6: e25454.
32. Stagni V, Oropallo V, Fianco G, Antonelli M, Cina I, Barila D (2014) Tug of war between survival and death: exploring ATM function in cancer. Int J Mol Sci 15: 5388-5409.
33. The Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumors. Nature 490: 61-70.
34. Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, Byrd P, Taylor M, Easton DF (2005) Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 97: 813-822.
35. Tommiska J, Bartkova J, Heinonen M, Hautala L, Kilpivaara O, Eerola H, Aittomaki K, Hofstetter B, Lukas J, von Smitten K, Blomqvist C, Ristimaki A, Heikkila P, Bartek J, Nevanlinna H (2008) The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2- deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene 27: 2501-2506.
36. Treilleux I, Chapot B, Goddard S, Pisani P, Angele S, Hall J (2007) The molecular causes of low ATM protein expression in breast carcinoma; promoter methylation and levels of the catalytic subunit of DNA-dependent protein kinase. Histopathology 51: 63-69.
37. Troncale S, Barbet A, Coulibaly L, Henry E, He B, Barillot E, Dubois T, Hupe P, de Koning L (2012) NormaCurve: a SuperCurve-based method that simultaneously quantifies and normalizes reverse phase protein array data. PLoS One 7: e38686.
38. Vo QN, Kim WJ, Cvitanovic L, Boudreau DA, Ginzinger DG, Brown KD (2004) The ATM gene is a target for epigenetic silencing in locally advanced breast cancer. Oncogene 23: 9432-9437.
39. Williamson CT, Muzik H, Turhan AG, Zamo A, OConnor MJ, Bebb DG, Lees-Miller SP (2010) ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 9: 347-357.
40. Yan D, Ng WL, Zhang X, Wang P, Zhang Z, Mo YY, Mao H, Hao C, Olson JJ, Curran WJ, Wang Y (2010) Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation. PLoS One 5: e11397.
41. Ye C, Cai Q, Dai Q, Shu XO, Shin A, Gao YT, Zheng W (2007) Expression patterns of the ATM gene in mammary tissues and their associations with breast cancer survival. Cancer 109: 1729-1735.
42. Zhang X, Nie Y, Li X, Wu G, Huang Q, Cao J, Du Y, Li J, Deng R, Huang D, Chen B, Li S, Wei B (2014) MicroRNA-181a functions as an oncomir in gastric cancer by targeting the tumour suppressor gene ATM. Pathol Oncol Res; e-pub ahead of print 16 February 2014.
43. Zhou Y, Wan G, Spizzo R, Ivan C, Mathur R, Hu X, Ye X, Lu J, Fan F, Xia L, Calin GA, Ellis LM, Lu X (2014) miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Mol Oncol 8: 83-92.